Risk stratification of ventricular arrhythmias in patients with systolic heart failure
- PMID: 20224387
- DOI: 10.1097/HCO.0b013e3283387a73
Risk stratification of ventricular arrhythmias in patients with systolic heart failure
Abstract
Purpose of review: Sudden cardiac death (SCD) accounts for an estimated 310 000 deaths in the United States each year. Implantable cardioverter defibrillator (ICD) implantation has revolutionized SCD prevention in heart failure patients, but only a minority of patients with ICDs receive appropriate therapy for ventricular arrhythmias. At present, the selection of patients for ICD is based largely on left ventricular ejection fraction and heart failure, but further risk stratification is still needed to determine which patients will derive the greatest benefit.
Recent findings: Multicenter studies have failed to confirm the utility of microvolt T-wave alternans to predict ventricular arrhythmias in patients with ICDs. Additional risk stratification tools including resting ECG characteristics, nonsustained ventricular tachycardia, tests of autonomic function, and cardiac MRI demonstrate predictive value but have limited clinical applicability at present.
Summary: Depressed ejection fraction with symptomatic heart failure remains the most powerful predictor of SCD and is the primary method currently used in patient care decisions. Progress continues in evaluation of additional risk factors and risk stratification tools, but no one test or combination of tests is definitive for prediction of arrhythmic events.
Similar articles
-
Utility of microvolt T-wave alternans to predict sudden cardiac death in patients with cardiomyopathy.Curr Opin Cardiol. 2007 Jan;22(1):25-32. doi: 10.1097/HCO.0b013e328011aa49. Curr Opin Cardiol. 2007. PMID: 17143041 Review.
-
Microvolt T-wave alternans and other noninvasive predictors of serious arrhythmic events in patients with an implanted cardioverter-defibrillator.Kardiol Pol. 2012;70(5):447-55. Kardiol Pol. 2012. PMID: 22623232
-
Microvolt T-wave alternans for the risk stratification of dangerous ventricular arrhythmias in patients with previously implanted automatic cardioverter-defibrillator.Kardiol Pol. 2011;69(6):580-5. Kardiol Pol. 2011. PMID: 21678296
-
Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death?Eur Heart J. 2013 Jul;34(26):1964-71. doi: 10.1093/eurheartj/eht109. Epub 2013 May 3. Eur Heart J. 2013. PMID: 23644180 Review.
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
Cited by
-
Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.J Interv Card Electrophysiol. 2017 Sep;49(3):263-270. doi: 10.1007/s10840-017-0260-8. Epub 2017 Jul 3. J Interv Card Electrophysiol. 2017. PMID: 28674918
-
Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update.J Clin Med. 2018 Nov 10;7(11):436. doi: 10.3390/jcm7110436. J Clin Med. 2018. PMID: 30423853 Free PMC article. Review.
-
Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.J Cardiovasc Transl Res. 2016 Dec;9(5-6):421-428. doi: 10.1007/s12265-016-9713-1. Epub 2016 Oct 31. J Cardiovasc Transl Res. 2016. PMID: 27798759 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials